Combined Rehabilitation With ALA, ALC, Resveratrol and Vitamin D in Discogenic Sciatica in Young People

University of Palermo

Status: Completed

Conditions: Sciatic Radiculopathy

Treatments: Other: rehabilitation; Other: supplementation

Study type: Interventional

Funder types: Other

Identifiers

NCT06078163

MFR0042023

Details and patient eligibility

About

The objective of this Interventional case-control clinical study is to evaluate the effectiveness of physiotherapy combined with the administration of Alpha Lipoic Acid, L-acetylcarnitine, Resvelatrol, Vit D3 in the treatment of sciatica due to herniated disc in young patients.

The main questions we intend to answer are:

• Is this combined treatment more effective in reducing pain?
• Is the combined treatment useful for improving postural alterations, reducing the intake of painkillers and the number of days of absence from work and improving the quality of life?

Enrollment: 130 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age 18-45 years
• pain with NRS scale score between 5 and 7 points
• symptoms attributable to lumbosciatica which occurred no more than 4 weeks ago
• pharmacological wash out of NSAIDs and corticosteroids for at least a week
• presence of L4-L5, L5-S1 disc herniation diagnosed with lumbar MRI performed within 3 months
• absence of ongoing infectious episodes;
• written consent for participation in the study.

Exclusion criteria

• Altered states of consciousness;
• Sciatica not of disc origin
• Neurological disorders
• Presence of scoliosis >20° of Cobb
• Previous spinal surgery
• Pregnancy and/or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

130 participants in 2 patient groups, including a placebo group

Treatment Group

Experimental group

Description:

Treatment Group was composed of patients who will undergo daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, Vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions

Treatment:

Other: supplementation

Other: rehabilitation

Control Group

Placebo Comparator group

Description:

Control Group was composed of patients who will only undergo a rehabilitation protocol lasting 20 sessions.

Treatment:

Other: rehabilitation